http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yang, Chungmo,Jeong, Soohyun,Ku, Seul,Lee, Kangwon,Park, Min Hee Elsevier 2018 Journal of controlled release Vol.279 No.-
<P><B>Abstract</B></P> <P>Nitric Oxide (NO) is a small molecule gasotransmitter synthesized by nitric oxide synthase in almost all types of mammalian cells. NO is synthesized by NO synthase by conversion of <SMALL>L</SMALL>-arginine to <SMALL>L</SMALL>-citrulline in the human body. NO then stimulates soluble guanylate cyclase, from which various physiological functions are mediated in a concentration-dependent manner. High concentrations of NO induce apoptosis or antibacterial responses whereas low NO circulation leads to angiogenesis. The bidirectional effect of NO has attracted considerable attention, and efforts to deliver NO in a controlled manner, especially through polymeric carriers, has been the topic of much research. This naturally produced signaling molecule has stood out as a potentially more potent therapeutic agent compared to exogenously synthesized drugs. In this review, we will focus on past efforts of using the controlled release of NO via polymer-based materials to derive specific therapeutic results. We have also added studies and our future suggestions on co-delivery methods with other gasotransmitters as a step towards developing multifunctional carriers.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Yang, Chungmo,Hwang, Hae Hyun,Jeong, Soohyun,Seo, Deokwon,Jeong, Yoon,Lee, Dong Yun,Lee, Kangwon Dove Medical Press 2018 International journal of nanomedicine Vol.13 No.-
<P><B>Purpose</B></P><P>Nitric oxide (NO) can be clinically applied at low concentrations to regulate angiogenesis. However, studies using small molecule NO donors (<I>N</I>-diazeniumdiolate, <I>S</I>-nitrosothiol, etc) have yet to meet clinical requirements due to the short half-life and initial burst-release profile of NO donors. In this study, we report the feasibility of methoxy poly(ethylene glycol)-b-poly(lactic-<I>co</I>-glycolic acid) (mPEG-PLGA) nanoparticles (NPs) as NO-releasing polymers (NO-NPs) for inducing angiogenesis.</P><P><B>Materials and methods</B></P><P>The mPEG–PLGA copolymers were synthesized by typical ring-opening polymerization of lactide, glycolide and mPEG as macroinitiators. Double emulsion methods were used to prepare mPEG–PLGA NPs incorporating hydrophilic NONOate (dieth-ylenetriamine NONOate).</P><P><B>Results</B></P><P>This liposomal NP encapsulates hydrophilic diethylenetriamine NONOate (70%±4%) more effectively than other previously reported materials. The application of NO-NPs at different ratios resulted in varying NO-release profiles with no significant cytotoxicity in various cell types: normal cells (fibroblasts, human umbilical vein endothelial cells and epithelial cells) and cancer cells (C6, A549 and MCF-7). The angiogenic potential of NO-NPs was confirmed in vitro by tube formation and ex vivo through an aorta ring assay. Tubular formation increased 189.8% in NO-NP–treated groups compared with that in the control group. Rat aorta exhibited robust sprouting angiogenesis in response to NO-NPs, indicating that NO was produced by polymeric NPs in a sustained manner.</P><P><B>Conclusion</B></P><P>These findings provide initial results for an angiogenesis-related drug development platform by a straightforward method with biocompatible polymers.</P>
Serum persistent organic pollutants (POPs) and prostate cancer risk: A case-cohort study
Lim, Jung-eun,Nam, Chungmo,Yang, Jiyeon,Rha, Koon Ho,Lim, Kyung-Min,Jee, Sun Ha Elsevier 2017 International journal of hygiene and environmental Vol.220 No.5
<P><B>Abstract</B></P> <P>It is still unclear whether persistent organic pollutants (POPs) exposure increases the prostate cancer incidence risk. This prospective cohort study evaluated the associations between serum POPs concentrations and prostate cancer risk.</P> <P>Within a case-cohort study, we identified 110 people diagnosed with prostate cancer and randomly selected 256 sub-cohort participants without prostate cancer. Serum concentrations of 32 polychlorinated biphenyl (PCB) congeners and 19 organochlorine pesticides (OCPs) were measured. The hazard ratios (HRs) and 95% confidence interval (95% CI) for determining the associations between POPs and risk of prostate cancer were estimated using the weighted Cox regression model.</P> <P>Compared to the lowest tertile, increased risks of prostate cancer incidence were observed in the upper tertile of following PCBs: the moderately chlorinated (HR: 4.19; 95% CI: 1.30–13.54), the highly chlorinated (HR: 4.14; 95% CI: 1.75–9.79), biologically persistent as CYP1A and CYP2B inducers (HR: 4.44; 95% CI: 1.33–14.83), the sum of non- dioxin-like (HR: 3.47; 95% CI: 1.21–9.98), and ∑PCBs (HR: 4.29; 95% CI: 1.52–12.08). In dose-response curves, ∑PCBs was associated with the increased risk of prostate cancer.</P> <P>Our findings suggested a possible role of POPs in the etiology of prostate cancer.</P> <P><B>Highlights</B></P> <P> <UL> <LI> The association of POPs and prostate cancer incidence risk was evaluated. </LI> <LI> Serum levels of PCBs and OCPs were measured. </LI> <LI> Both linear and non-linear analyses were conducted. </LI> <LI> PCBs and TEQ were associated with the increased risk of prostate cancer. </LI> <LI> Total OCPs was not associated with the prostate cancer risk. </LI> </UL> </P>